6.39

0.31% -0.02

After Hours: 6.38 -0.010 -0.16%

Abeona Therapeutics Inc (ABEO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Abeona Therapeutics Inc stock is traded at $6.39, with a volume of 162.01K. It is down -0.31% in the last 24 hours and down -2.74% over the past month. Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Previous Close:

$6.41

Open:

$6.46

24h Volume:

162.01K

Relative Volume:

0.61

Market Cap:

$277.78M

Revenue:

Net Income/Loss:

$-54.19M

P/E Ratio:

-2.1275

EPS:

-3.0035

Net Cash Flow:

$-37.34M

1W Performance:

+6.86%

1M Performance:

-2.74%

6M Performance:

+57.39%

1Y Performance:

+30.41%

1-Day Range:

$6.16

$6.46

1-Week Range:

$5.9339

$6.545

52-Week Range:

$3.05

$9.01

Abeona Therapeutics Inc Stock (ABEO) Company Profile

Name

Abeona Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

646-813-4701

Address

6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY

Employee

Twitter

@abeonabio

Next Earnings Date

2024-12-11

Latest SEC Filings

ABEO's Discussions on Twitter

Compare ABEO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABEO Abeona Therapeutics Inc	6.39	277.78M	0	-54.19M	-37.34M	-2.58
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-03-24	Initiated	H.C. Wainwright	Buy
May-30-24	Initiated	Stifel	Buy
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-18-20	Initiated	B. Riley FBR	Buy
Feb-10-20	Initiated	SVB Leerink	Outperform
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-26-19	Downgrade	Mizuho	Buy → Neutral
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy
Jun-05-18	Initiated	Seaport Global Securities	Buy
Nov-08-17	Initiated	SunTrust	Buy
Oct-16-17	Reiterated	H.C. Wainwright	Buy
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight
Oct-10-17	Initiated	Citigroup	Buy
Oct-05-17	Reiterated	Maxim Group	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-18-17	Reiterated	Maxim Group	Buy
Jun-22-17	Resumed	Jefferies	Buy
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy

View All

Abeona Therapeutics Inc Stock (ABEO) Latest News

Nov 28, 2024

Abeona Therapeutics Inc.'s (NASDAQ:ABEO) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St

Nov 28, 2024

StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to Hold - MarketBeat

Nov 28, 2024

Nov 27, 2024

What is HC Wainwright's Estimate for ABEO FY2024 Earnings? - MarketBeat

Nov 27, 2024

Nov 26, 2024

Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Sold by Propel Bio Management LLC - MarketBeat

Nov 26, 2024

Nov 25, 2024

Abeona shares retain Buy rating; H.C. Wainwright sees approval potential for pz-cel in RDEB - Investing.com UK

Nov 25, 2024

Abeona Therapeutics (NASDAQ:ABEO) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 25, 2024

Nov 22, 2024

Earnings call: Abeona Therapeutics Q3 2024 results and PZ cell update - Investing.com Canada

Nov 22, 2024

Nov 20, 2024

Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com - MarketBeat

Nov 20, 2024

Nov 19, 2024

ABEO: FDA Accepts BLA Re-Submission for Pz-cel PDUFA Date of April 29 - Smartkarma

Nov 19, 2024

Nov 18, 2024

(ABEO) Trading Report - Stock Traders Daily

Nov 18, 2024

Nov 15, 2024

Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

FDA decision on Abeona’s pz-cel for RDEB now expected by April 29 - Epidermolysis Bullosa News

Nov 15, 2024

Abeona Therapeutics: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024